- Details
- Description
About Fidaxomicin
Fidaxomicin is the first member of a class of narrow spectrum macrocyclic antibiotic drugs called tiacumicins. Fidaxomicin is minimally absorbed into the bloodstream when taken orally, is bactericidal, and selectively eradicates pathogenic Clostridioides difficile with relatively little disruption to the multiple species of bacteria that make up the normal, healthy intestinal microbiota. The maintenance of normal physiological conditions in the colon may reduce the probability of recurrence of Clostridioides difficile infection.
Clostridioides difficile-Associated Diarrhea
Indicated for treatment of Clostridioides difficile-associated diarrhea (CDAD)
200 mg PO BID x10 days
Dosage Modifications
Renal impairment
Dose adjustment not necessary
Hepatic impairment
Not studied; dose adjustment not necessary since minimally absorbed
Dosing Considerations
To reduce the development of drug-resistant bacteria and maintain the effectiveness, use only to treat infections that are proven or strongly suspected to be caused by C difficile
